NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

CHRS

Coherus Biosciences Inc

Apr 17 • 04:00PM ET

1.12

Dollar change +0.11
Percentage change 10.89	%

Healthcare • Biotechnology • USA • NASD

Peers: AMGN GILD ABBV VRTX REGN BIIB INCY BMRN NBIX EXEL

| Held by: VTI IWM VXF IWN SCHA VTWO VHT IWO IWC PRFZ

Scroll to Statements

Index	RUT	P/E	6.42	EPS (ttm)	0.17	Insider Own	3.98%	Shs Outstand	115.61M	Perf Week	50.90%
Market Cap	129.81M	Forward P/E	-	EPS next Y	-1.00	Insider Trans	0.00%	Shs Float	111.29M	Perf Month	23.44%
Income	28.51M	PEG	-	EPS next Q	-0.36	Inst Own	54.15%	Short Float	29.19%	Perf Quarter	-21.13%
Sales	266.96M	P/S	0.49	EPS this Y	-81.14%	Inst Trans	-15.50%	Short Ratio	16.20	Perf Half Y	23.06%
Book/sh	-1.14	P/B	-	EPS next Y	-2214.00%	ROA	5.26%	Short Interest	32.49M	Perf Year	-47.91%
Cash/sh	1.09	P/C	1.03	EPS next 5Y	-	ROE	-	52W Range	0.66 - 2.43	Perf YTD	-18.84%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-27.36%	ROI	17.40%	52W High	-53.91%	Beta	0.87
Dividend TTM	-	Quick Ratio	0.96	Sales past 5Y	-1.49%	Gross Margin	53.99%	52W Low	69.62%	ATR (14)	0.10
Dividend Ex-Date	-	Current Ratio	1.21	EPS Y/Y TTM	110.41%	Oper. Margin	-36.78%	RSI (14)	61.92	Volatility	11.47% 11.57%
Employees	228	Debt/Eq	-	Sales Y/Y TTM	3.78%	Profit Margin	10.68%	Recom	1.60	Target Price	4.83
Option/Short	Yes / Yes	LT Debt/Eq	-	EPS Q/Q	38.52%	Payout	0.00%	Rel Volume	1.48	Prev Close	1.01
Sales Surprise	22.64%	EPS Surprise	-43.98%	Sales Q/Q	-40.84%	Earnings	Mar 10 AMC	Avg Volume	2.01M	Price	1.12
SMA20	25.93%	SMA50	13.26%	SMA200	-6.06%	Trades		Volume	2,973,523	Change	10.89%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-16-24	Downgrade	UBS	Buy → Neutral	$4 → $1.50
Nov-17-23	Initiated	Robert W. Baird	Outperform	$11
Nov-08-23	Downgrade	Maxim Group	Buy → Hold
Jul-24-23	Initiated	Citigroup	Buy	$12
May-01-23	Initiated	Truist	Buy	$24
Mar-28-23	Upgrade	UBS	Neutral → Buy	$11
Jun-14-22	Initiated	UBS	Neutral	$7
Mar-07-22	Downgrade	JP Morgan	Overweight → Neutral	$15
Jul-16-20	Initiated	BofA Securities	Neutral	$20
Apr-17-20	Initiated	SunTrust	Buy	$26
Aug-13-19	Initiated	Mizuho	Buy
Aug-02-19	Reiterated	Maxim Group	Buy	$25 → $27
Aug-02-19	Reiterated	H.C. Wainwright	Buy	$28 → $29
Jun-11-19	Initiated	Barclays	Overweight	$30
May-07-19	Initiated	H.C. Wainwright	Buy	$28
Aug-28-18	Initiated	H.C. Wainwright	Buy	$28
Mar-09-18	Reiterated	Maxim Group	Buy	$20 → $15
Aug-08-17	Reiterated	JP Morgan	Overweight	$32 → $25
Jun-13-17	Reiterated	Maxim Group	Buy	$44 → $40
May-05-17	Initiated	BMO Capital Markets	Outperform	$54

Show Previous Ratings

Today 05:53AM	Coherus BioSciences: Cleaning The Balance Sheet And Developing New Drugs (Seeking Alpha) +10.89%
Apr-15-25 09:44AM	Coherus divests Udenyca franchise to Intas for up to $558.4m (Pharmaceutical Technology) +8.76%
Apr-14-25 08:00AM	Coherus Completes Strategic Transformation with Successful Divestiture of UDENYCA Franchise (GlobeNewswire) +16.59%
Apr-01-25 08:00AM	Coherus Announces Repurchase of Approximately $170 Million of Convertible Notes (GlobeNewswire)
Mar-25-25 04:30PM	Coherus to Present Data from a Phase 1 Dose Expansion Study of CHS-114, a Cytolytic Antibody Targeting Chemokine Receptor 8 (CCR8), at the 2025 American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire) -5.81%
07:10AM	Loading…
Mar-21-25 07:10AM	Lazard Enhanced Opportunities Portfolio Q4 2024 Commentary (SeekingAlpha) +8.83%
Mar-14-25 12:15PM	Biotech Alert: Searches spiking for these stocks today (TipRanks)
Mar-12-25 03:23PM	Coherus BioSciences, Inc. (CHRS): A Bull Case Theory (Insider Monkey) -6.67%
Mar-11-25 01:46PM	Q4 2024 Coherus BioSciences Inc Earnings Call (Thomson Reuters StreetEvents)
03:02AM	Coherus BioSciences Inc (CHRS) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
Mar-10-25 04:32PM	Coherus BioSciences: Q4 Earnings Snapshot (Associated Press Finance)
04:12PM	Coherus BioSciences Reports Fourth Quarter, Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire)
Mar-07-25 07:06AM	What To Expect From Coherus BioSciences Inc (CHRS) Q4 2024 Earnings (GuruFocus.com)
Mar-03-25 08:30AM	Coherus to Report Fourth Quarter and Full Year 2024 Financial Results on March 10, 2025 (GlobeNewswire) -9.46%
Feb-24-25 09:08AM	Coherus Management to Participate at the 45th Annual TD Cowen Health Care Conference (GlobeNewswire) +7.48%
08:39AM	Loading…
Feb-12-25 08:39AM	Coherus BioSciences, Inc. (CHRS): A Bull Case Theory (Insider Monkey)
Jan-22-25 07:00AM	Coherus Presents Final Phase 2 Clinical Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025 (GlobeNewswire)
Jan-08-25 08:00AM	Coherus Management to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-18-24 08:30AM	Coherus to Present Final Phase 2 Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025 (GlobeNewswire) -8.19%
Dec-03-24 07:00AM	Coherus Announces Agreement to Divest UDENYCA Franchise for up to $558 million to Intas Pharmaceuticals Ltd. (GlobeNewswire) +24.82%
06:06AM	Coherus, sharpening immuno-oncology focus, sells another biosimilar for over $500M (BioPharma Dive)
Nov-27-24 04:01PM	Coherus Management to Participate in the 2024 Citi Global Healthcare Conference (GlobeNewswire)
Nov-07-24 01:09PM	Q3 2024 Coherus BioSciences Inc Earnings Call (Thomson Reuters StreetEvents) +13.29%
02:26AM	Coherus BioSciences Inc (CHRS) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid ... (GuruFocus.com)
Nov-06-24 05:15PM	Coherus BioSciences (CHRS) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:11PM	Coherus BioSciences: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Coherus BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Nov-05-24 08:08AM	Coherus BioSciences Inc (CHRS) Q3 2024: Everything You Need to Know Ahead of Earnings (GuruFocus.com) +9.10%
Oct-30-24 04:20PM	Coherus to Report Third Quarter 2024 Financial Results on November 6, 2024 (GlobeNewswire)
Oct-09-24 06:01PM	Coherus BioSciences Inc (CHRS) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
07:24AM	Loading…
Sep-28-24 07:24AM	Coherus BioSciences, Inc. (CHRS): Worst 52-Week Low Stock to Buy Now (Insider Monkey)
Sep-25-24 11:28AM	Short Interest Surges to 21.83% as Coherus BioSciences, Inc. (CHRS) Faces Revenue Challenges (Insider Monkey)
Aug-08-24 05:50PM	Coherus BioSciences (CHRS) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +10.85%
04:45PM	Coherus BioSciences: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Coherus BioSciences Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Aug-01-24 09:00AM	Coherus to Report Second Quarter 2024 Financial Results on August 8, 2024 (GlobeNewswire) -7.14%
Jun-28-24 07:49AM	PTC faces another Duchenne drug rejection; Coherus sells Humira biosimilar (BioPharma Dive)
Jun-27-24 08:26AM	Coherus BioSciences Announces Divestiture of YUSIMRY (adalimumab-aqvh) in a $40 Million Upfront All Cash Transaction (GlobeNewswire)
Jun-05-24 09:00AM	Coherus BioSciences Appoints Rita Karachun, CPA, CGMA to its Board of Directors (GlobeNewswire)
May-30-24 09:00AM	Coherus Management to Present at the 2024 Jefferies Global Healthcare Conference (GlobeNewswire)
May-23-24 05:51PM	Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine receptor 8 (CCR8) Antibody, CHS-114, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
09:00AM	Coherus Management to Present at the TD Cowen 5th Annual Oncology Innovation Virtual Summit: Insights for ASCO & EHA (GlobeNewswire)
May-13-24 09:23AM	Truist Securities Trims Price Target on Coherus BioSciences to $7 From $8, Maintains Buy Rating (MT Newswires) +10.00%
May-10-24 04:45PM	Coherus BioSciences, Inc. (NASDAQ:CHRS) Q1 2024 Earnings Call Transcript (Insider Monkey) -10.38%
May-09-24 05:15PM	Coherus BioSciences (CHRS) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:12PM	Coherus BioSciences: Q1 Earnings Snapshot (Associated Press Finance)
04:01PM	Coherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
07:30AM	Coherus Announces Full Repayment of Pharmakon Advisors $75 Million Term Loan (GlobeNewswire)
May-08-24 09:00AM	Coherus Announces Clinical Collaboration with the Cancer Research Institute for a Novel Combination Evaluating LOQTORZI (toripalimab-tpzi) with ENB Therapeutics' ENB-003 for the Treatment of Ovarian Cancer (GlobeNewswire)
May-01-24 04:30PM	Coherus to Report First Quarter 2024 Financial Results on May 9, 2024 (GlobeNewswire) +5.10% +5.34%
Apr-24-24 10:02AM	Coherus Announces Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire) -7.34%
Apr-08-24 08:30AM	Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual Meeting (GlobeNewswire)
Mar-16-24 03:35PM	Coherus BioSciences, Inc. (NASDAQ:CHRS) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-14-24 06:28PM	Why Coherus Biosciences Stock Tumbled on Thursday (Motley Fool) -5.65%
07:15AM	Q4 2023 Coherus BioSciences Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-13-24 05:32PM	Coherus BioSciences Inc (CHRS) Reports Growth in Net Revenue for Q4 and Full Year 2023 Despite ... (GuruFocus.com)
04:13PM	Coherus BioSciences: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update (GlobeNewswire)
Mar-05-24 04:01PM	Coherus to Report Fourth Quarter and Full Year 2023 Financial Results on March 13, 2024 (GlobeNewswire)
Mar-04-24 01:00AM	Coherus Completes Divestiture of Ophthalmology Franchise (GlobeNewswire) -5.81%
Feb-23-24 05:33PM	Coherus BioSciences Announces New Employment Inducement Grants (GlobeNewswire)
Feb-21-24 08:30AM	Coherus Announces U.S. Launch of UDENYCA ONBODY a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv (GlobeNewswire)
Feb-06-24 05:16PM	Why Coherus BioSciences Stock Jumped Today (Motley Fool) +14.85%
Feb-05-24 08:00AM	Coherus Amends Term Loan Agreement with Pharmakon Advisors, LP (GlobeNewswire)
Jan-23-24 11:37AM	Why Coherus BioSciences Stock Is Sinking Today (Motley Fool) -6.98%
Jan-22-24 03:41PM	Why Coherus Biosciences Popped Today (Motley Fool) +5.74%
08:38AM	Why Is Coherus BioSciences (CHRS) Stock Up 17% Today? (InvestorPlace)
01:15AM	Coherus Announces Agreement to Divest Ophthalmology Franchise to Sandoz in $170 Million Upfront All Cash Deal (GlobeNewswire)
Jan-18-24 04:05PM	Coherus Presents Positive Phase 2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2024 ASCO GI Cancers Symposium (GlobeNewswire)
Jan-12-24 03:06AM	Here's Why Aristotle Small Cap Equity Strategy Sold Coherus BioSciences (CHRS) (Insider Monkey)
Jan-04-24 08:00AM	INOVIO and Coherus Announce Clinical Collaboration to Advance Development of INO-3112 in Combination with LOQTORZI (toripalimab-tpzi) (PR Newswire)
Jan-03-24 09:00AM	Coherus BioSciences Management to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-02-24 08:29AM	Coherus Announces U.S. Launch of LOQTORZI (GlobeNewswire) -5.71%
Dec-28-23 03:45PM	Why Coherus BioSciences Stock Jumped Today (Motley Fool) +20.45%
11:07AM	Coherus (CHRS) Stock Rallies on FDA Nod for Udenyca Onbody (Zacks)
Dec-27-23 05:07PM	These Stocks Moved the Most Today: Tesla, Apple, Coinbase, MicroStrategy, Iovance, NetEase, and More (Barrons.com) +23.39%
01:06PM	These Stocks Are Moving the Most Today: Tesla, Apple, Coinbase, MicroStrategy, Iovance, NetEase, and More (Barrons.com)
Dec-26-23 04:01PM	Coherus Announces FDA Approval of UDENYCA ONBODY , a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv (GlobeNewswire) +7.92%
Dec-24-23 09:45AM	2 Small Cap Stocks That Could Go Parabolic in 2024, According to Wall Street (Motley Fool)
Dec-22-23 05:00PM	Coherus BioSciences Announces New Employment Inducement Grants (GlobeNewswire) +7.92%
Dec-11-23 08:30AM	Coherus Announces Updated NCCN Clinical Practice Guidelines Positioning LOQTORZI (toripalimab-tpzi) as Preferred Category 1 Regimen for First-Line Treatment of Cancer of the Nasopharynx (GlobeNewswire)
Dec-07-23 05:55PM	Coherus BioSciences Announces CFO Transition Plans (GlobeNewswire)
Dec-06-23 04:00AM	Coherus Presents Phase 1/2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2023 ESMO Immuno-Oncology Congress (GlobeNewswire)
Nov-28-23 11:16AM	Coherus and Junshi Biosciences Announce Publication of Positive Final Overall Survival Results of JUPITER-02, a Phase 3 Trial Evaluating LOQTORZI (toripalimab-tpzi) as Treatment for Nasopharyngeal Carcinoma, in the Journal of the American Medical Association (GlobeNewswire) +8.76%
Nov-10-23 03:15PM	Why Coherus BioSciences Was Plummeting This Week (Motley Fool)
Nov-07-23 03:37PM	Why Coherus Biosciences Stock Dropped Today (Motley Fool) -30.23%
10:46AM	Coherus BioSciences, Inc. (NASDAQ:CHRS) Q3 2023 Earnings Call Transcript (Insider Monkey)
10:19AM	Q3 2023 Coherus BioSciences Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-06-23 05:13PM	Coherus BioSciences Inc (CHRS) Reports 27% Rise in Q3 2023 Net Revenue (GuruFocus.com)
04:43PM	Coherus BioSciences: Q3 Earnings Snapshot (Associated Press Finance)
04:07PM	Coherus BioSciences Reports Third Quarter 2023 Financial Results and Business Highlights (GlobeNewswire)
Nov-03-23 08:30AM	Coherus Presents Data from Next-generation Immuno-oncology Programs at 38th Annual Meeting of Society for Immunotherapy of Cancer (SITC) (GlobeNewswire) +8.73%
Nov-02-23 08:00PM	Coherus BioSciences to Participate at Upcoming November Investor Conferences (GlobeNewswire)
Nov-01-23 10:01AM	Vericel Corporation (VCEL) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release (Zacks)
Oct-30-23 06:00PM	Coherus BioSciences to Report Third Quarter 2023 Financial Results on November 6, 2023 (GlobeNewswire) +14.02% +11.30%
05:43PM	Why Coherus BioSciences Stock Soared Today (Motley Fool)
Oct-27-23 03:07PM	Coherus and Junshi Biosciences Announce FDA Approval of LOQTORZI (toripalimab-tpzi) in All Lines of Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC) (GlobeNewswire)
Oct-24-23 07:41PM	Coherus BioSciences Announces New Employment Inducement Grants (GlobeNewswire) -11.16%
Oct-14-23 12:30PM	Coherus Announces Toripalimab Data at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (GlobeNewswire)
Oct-11-23 10:42AM	Load Up, Says Citigroup, About These 2 Strong Buy Stocks (TipRanks)

Coherus BioSciences, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of biosimilar therapeutics. Its products include UDENYCA and LOQTORZI. The company was founded by Dennis M. Lanfear, Stuart E. Builder, Dr. Alan Herman, Doug Farrar and Steve Glover in September 2010 and is headquartered in Redwood City, CA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CHRS

Coherus Biosciences Inc

Upgrade your FINVIZ experience